Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Multiple Research Teams Unable to Confirm High-Profile Alzheimer’s Study

Published: Friday, May 24, 2013
Last Updated: Friday, May 24, 2013
Bookmark and Share
Teams of highly respected Alzheimer’s researchers failed to replicate what appeared to be breakthrough results for the treatment of this brain disease when they were published last year in the journal Science.

Those results, presented online Feb. 9, 2012, suggested that the drug bexarotene (marketed as Targretin) could rapidly reverse the buildup of beta amyloid plaques (Aβ)—a pathological hallmark of Alzheimer’s disease—in the brains of mice. According to the authors of the 2012 report, drug treatment quickly removed most of the plaques and brought rapid reversal of the pathological, cognitive and memory deficits related to the onset of Alzheimer’s.

However, the new reports from extensive and carefully controlled studies did not show any reduction in the number of plaques or total area occupied by the plaques during or after treatment. These results are described in three “technical comments”—one of which comes from researchers at the University of Chicago, Northwestern University, Massachusetts General Hospital, Washington University in St. Louis and the University of Tubingen in Germany—to be published in the May 24 issue of Science.

“The drug has no impact on plaque burden in three strains that exhibit Aβ amyloidosis,” according to that group's comment. “We have failed to support earlier findings by Cramer et al that Targretin is efficacious in reducing plaque burden in transgenic mouse models of cerebral Aβ deposition.”

Comment co-author Sangram Sisodia, professor of neurosciences at the University of Chicago, said he and his colleagues were curious about the initial report in 2012.

“We were surprised and excited, even stunned, when we first saw these results presented at a small conference,” said Sisodia. “The mechanism of action made some sense, but the assertion that they could reduce the areas of plaque by 50 percent within three days, and by 75 percent in two weeks, seemed too good to be true.”

“We all went back to our labs and tried to confirm these promising findings,” Sisodia added. “We repeated the initial experiments—a standard process in science. Combined results are really important in this field. None of us found anything like what they described in the 2012 paper.”

The researchers found no effects on plaque burden in three different strains of mice that were treated with bexarotene.

The discrepancy, besides being disappointing, also raises concerns about patient safety. The Food and Drug Administration approved bexarotene in December 1999 for a very specific use: treatment of refractory cutaneous T-cell lymphoma, a type of skin cancer. Once approved, the drug became legally available by prescription for “off-label” uses as well.

“Anecdotally, we have all heard that physicians are treating their Alzheimer's patients with bexarotene, a cancer drug with severe side effects,” said co-author Robert Vassar, professor of cell and molecular biology at Northwestern University Feinberg School of Medicine. “This practice should be ended immediately, given the failure of three independent research groups to replicate the plaque-lowering effects of bexarotene.”

Bexarotene has never been tested as a treatment for Alzheimer’s disease in humans, not even to determine the optimal dose or duration of treatment. This drug has significant side effects, including major blood-lipid abnormalities, pancreatitis, liver function test abnormalities, thyroid axis alterations, leucopenia, headaches, fatigue, weight gain, depression, nausea, vomiting, constipation and rash.

The two other technical comments came from research teams led by Kevin Felsenstein, Todd Golde, David Borchelt and colleagues at the University of Florida, and by Bart DeStrooper and colleagues at the University of Leuven, Belgium.

There is no cure or effective treatment for Alzheimer’s disease, which is a progressive type of dementia that occurs when nerve cells in the brain die. When Alzheimer’s was first identified in 1906, it was considered a rare disorder. Today, Alzheimer’s is the most common cause of dementia; an estimated 5.3 million Americans have the disease.

This work was supported by the Cure Alzheimer’s Fund. Additional authors include Karthikeyan Veeraraghavalu of the University of Chicago; Rudolph Tanzi, Can Zhang and Sean Miller of Massachusetts General Hospital; Jasmin K. Hefendehl and Mathias Jucker of the University of Tübingen; Tharinda W. Rajapaksha and Robert Vassar of Northwestern University Feinberg School of Medicine; and Jason Ulrich and David M. Holtzman from the Washington University School of Medicine.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Protein Aggregation After Heat Shock Is An Organized, Reversible Response
New study finds protein aggregation after heat exposure is a reversible cellular process, not unrecoverable damage from misfolding.
Friday, September 11, 2015
Computer Modeling Shows Crucial Function of Water Molecules in Proteins
Scientists used molecular simulations that modeled a potassium channel and its immediate cellular environment, atom for atom.
Wednesday, July 31, 2013
Watery Research Theme to Flow Through New Tokmakoff Lab
Andrei Tokmakoff to use the world’s shortest infrared light pulses to pluck molecular bonds.
Friday, March 15, 2013
Study Points to New Target for Cancers Resistant to Certain Drugs
A more sensitive method to analyze protein interactions has uncovered a new way that cancer cells may use the cell-surface molecule HER3 to drive tumor progression following treatment with HER1 and HER2 inhibitors.
Tuesday, September 11, 2012
Scientific News
FNIH Launches Project to Evaluate Biomarkers in Cancer Patients
Company has announced that it has launched a new project to evaluate the effectiveness of liquid biopsies as biomarkers in colorectal cancer patients.
HIV Particles Used to Trap Intact Mammalian Protein Complexes
Belgian scientists from VIB and UGent developed Virotrap, a viral particle sorting approach for purifying protein complexes under native conditions.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
Computational Model Finds New Protein-Protein Interactions
Researchers at University of Pittsburgh have discovered 500 new protein-protein interactions (PPIs) associated with genes linked to schizophrenia.
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Controlling RNA in Living Cells
Modular, programmable proteins can be used to track or manipulate gene expression.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Potential Target for Revolutionary Antibiotics
An international team of including the Lomonosov Moscow State University researchers discovered which enzyme enables Escherichia coli bacterium (E. coli) to breathe.
DNA Barcodes Gone Wild
A team of researchers at University of Toronto’s Donnelly Centre and Sinai Health System’s Lunenfeld-Tanenbaum Research Institute (LTRI) has developed a new technology that can stitch together DNA barcodes inside a cell to simultaneously search amongst millions of protein pairs for protein interactions.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!